HOME >> BIOLOGY >> NEWS
Umbilical cord blood transplants, bone marrow transplants save lives

MAYWOOD, Ill. Umbilical cord blood and bone marrow transplants at Loyola University are curing or slowing the progression of many cancers originating in the bone marrow (i.e., leukemia, myeloma) or lymphatic system (lymphoma).

More than 106,000 people in the U.S. each year are diagnosed with these life-threatening diseases.

"Even if other treatments have produced no results, a bone marrow transplant may save the patient's life," said Dr. Patrick J. Stiff, director of the Cardinal Bernardin Cancer Center and the Bone Marrow Transplant Program at Loyola University Medical Center, Maywood, Ill. Patients unable to find a matching bone marrow donor may have an alternative with umbilical cord blood (CB) transplantation.

Loyola's unique method of preparing the umbilical cord blood enables more stem cells to survive, according to Stiff, who also is professor of Medicine and Pathology, Loyola University Chicago Stritch School of Medicine.

A transplant provides the patient with healthy, new stem cells to develop a new immune system. And it's working.

Holly Drucker, 30, of Chicago's north side; Adam McGillen, 25, of Sandwich, Ill.; Moira Minielly, 39, of Wilmette, Ill.; and Donna Marasco, 45, of Bolingbrook, Ill., were dying of cancer when they arrived at Loyola's Cardinal Bernadin Cancer Center during the past six years. At Loyola, Holly and Adam underwent umbilical cord blood transplant for non-Hodgkin's lymphoma. Moira, diagnosed with non-Hodgkin's lymphoma, and Donna, with chronic myelogenous leukemia, underwent bone marrow transplant at Loyola. Today all four are leading productive, happy lives.

Loyola has the largest bone marrow transplantation program in the Midwest, performing 160 transplants each year. It is a participating center in the National Marrow Donor Program network.

The latest statistics from the National Marrow Donor Program Network show the actual one-year patient su
'"/>

Contact: Joanne Swanson
jswanson@lumc.edu
708-216-2445
Loyola University Health System
1-Jun-2004


Page: 1 2 3

Related biology news :

1. Umbilical cord matrix, a rich new stem cell source, study shows
2. Duke Study Shows Umbilical Cord Blood Transplant Is Viable Treatment For Genetic Disorders
3. Experimental drug shown to block mutant protein causing blood disease
4. IBD (Crohns, Colitis) joins cancer, inflammatory diseases in associated blood vessel growth
5. A probable cause for high blood pressure identified - shows links with diabetes
6. Probing the surface of white blood cells to enhance immune system medicine
7. Streptococcus infects humans by thwarting blood clotting
8. Strep disrupts blood clotting to infect humans
9. Nucleic acid-amplification testing further safeguards nations blood supply
10. Hopkins scientists use blood proteins to detect ovarian cancer
11. Marijuana ingredient inhibits VEGF pathway required for brain tumor blood vessels

Post Your Comments:
(Date:4/23/2014)... term for novels and films which focus on the consequences ... how these fictions serve as a mental laboratory that allows ... imagine other living conditions. , "Global warming is much ... is also a cultural phenomenon in which meaning is being ... see. And there are so many of them now that ...
(Date:4/23/2014)... biomedical engineer at the University of Houston (UH) is ... transfusions safer. His work is supported by a $1.8 ... , Blood transfusions save millions of lives every ... Without them, for instance, routine surgeries would become life ... strong evidence that transfusions of red blood cells stored ...
(Date:4/22/2014)... to behave at the dinner tablecut up their food and ... Eating Behaviors , found that when 6-10 year old children ... such as drumsticks, whole apples, or corn on the cob ... cut. "They were twice as likely to disobey adults ... Professor and Director of the Cornell Food and Brand Lab. ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Biting vs. chewing 2
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
Cached News: